http://www.texytipografia.com/more.html
We are a biopharmaceutical company focusedon developing, and commercializing small moleculwe drugs to extend and enhancs the lives of patients with severe medical including cancer and chronix inflammatory diseases. We have three clinical-staged drug candidates and several drug candidatesa in the preclinical anddiscovery stages, each of which has a distinct chemical structure, mechanism of action, and market Each of our drug candidatesz was discovered and developed internallg using our proprietary, unique chemical compound librar and integrated discovery engine.
In October as amended in June we entered into a globalocollaborative development, commercialization and license or the GSK Agreement, with GlaxoSmithKline, or GSK, for the joint developmentg and commercialization of elesclomol, one of our oncolog drug candidates. In Decembeer 2008, we entered into a collaborativelicensde agreement, or the Roche Agreement, with Hoffmann-La Roche, or Roche, for our CRACM inhibitof program, which is currently in the lead optimization We retain all rights to our other drug candidatesd and programs.
We believe that our demonstratexd ability to generate new drug candidates from ourdiscovery platform, our abilithy to effectively enroll and conduct clinicap trials, and our ability to enter into partnerships with leading multinational pharmaceutical companies are important competitive ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment